Royalty Pharma plc MorphoSys Transaction Conference Call Transcript
Ladies and gentlemen, thank you for standing by. Welcome to Royalty Pharma's conference call on the MorphoSys transaction. I would now like to turn the call over to George Grofik, SVP, Head of Investor Relations and Communications. Please go ahead, sir.
Good morning and good afternoon to everyone on the call. Thank you for joining us to review Royalty Pharma's transaction with MorphoSys. You can find the slides for this call on the Investors page of our website at royaltypharma.com.
Moving to Slide 3, I'd like to remind you that information presented in this call contains forward-looking statements that involve known and unknown risks, uncertainties and other factors may cause actual results to differ materially. I refer you to our 10-K on file with the SEC for a discussion of these risks.
And with that, please advance to Slide 4. Our speakers on the call today are Pablo Legorreta Founder and Chief Executive Officer; Chris Hite, EVP, Vice Chairman; Marshall Urist
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |